Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump

, MT Newswires -  8:11 AM ET 3/28/2025 Company News

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

08:11 AM EDT, 03/28/2025 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) said Friday that it signed an exclusive license agreement with Novo Nordisk ( NVO ) for LX9851, a drug targeting obesity and associated metabolic disorders, sending shares up more than 94% in premarket activity.

Under the agreement, Novo Nordisk ( NVO ) gains the exclusive worldwide rights to develop, manufacture, and commercialize LX9851 across all indications.

Lexicon said it will be responsible for the completion of investigational new drug application-enabling activities for LX9851, while Novo Nordisk ( NVO ) will take over responsibility for filing the application and all subsequent development, manufacturing, and commercialization efforts.

Under the deal, Lexicon is eligible to receive up to $75 million in upfront and near-term milestone payments, a potential for $1 billion in development, regulatory, and sales milestones and tiered royalties on net sales.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.